ActoGeniX is a biopharmaceutical company focused on the development and commercialization of ActoBiotics™, a novel class of biopharmaceuticals for the targeted treatment of severe gastrointestinal diseases, metabolic diseases, immune disorders and allergies. ActoBiotics™ are based on the delivery of therapeutic proteins by living lactic acid bacteria. These products can be orally administered and are designed to be safer and more effective than injected biopharmaceuticals. ActoGeniX has recently completed a phase 2 clinical trial with AG011 for treatment of inflammatory bowel disease. During the second half of 2009 the Company also started a phase 1B clinical trial with AG013 for treatment and prevention of oral mucositis in cancer patients. ActoGeniX possesses a strong and broad intellectual property portfolio encompassing 20 distinct patent families.

Web: www.actogenix.com